GLP-1 treatment is reaching younger children faster than the public debate suggests
A new national analysis from researchers at NYU Langone Health shows that weight-loss drugs in the GLP-1 class are still used infrequently among young children with obesity in the United States, but prescribing has accelerated at a remarkable rate since 2019. The study, published online September 4 in Pediatrics, focuses on children ages 8 to 11 who have obesity but do not have diabetes, a group that has received far less public attention than teenagers and adults in discussions about these medicines.
The central finding is two-sided. On one hand, the drugs remain rare in absolute terms for young children. On the other, growth has been extremely fast. Researchers found that the share of children ages 8 to 11 with obesity and without diabetes who were prescribed GLP-1 receptor agonists rose from 0.03% in 2019 to 9.3% in 2026. Across that period, 20,282 children in that age group received prescriptions. The medications referenced in the report include Saxenda, Wegovy, and Zepbound.
That contrast matters because it changes how the trend should be understood. The study does not describe a system in which GLP-1s have become routine pediatric care for younger children. Instead, it describes a treatment category that is emerging quickly from a very low baseline, with clinicians increasingly using it in carefully selected cases, especially where obesity is severe and already linked to other health problems.
Who is receiving the drugs
The study found that older children remain somewhat more likely than younger children to receive these prescriptions. Among children with obesity, 0.6% of those ages 8 to 11 were prescribed the drugs, compared with 0.9% of adolescents ages 12 to 17. That gap persisted even though clinical guidelines permit use for obesity in children as young as 8.
The data also show that prescribing is not evenly distributed across pediatric patients. Girls were more likely than boys to receive the medications. Most children who received GLP-1 prescriptions had severe obesity, accounting for 93.7% of those treated. Severe obesity in this context means a body mass index far above that of nearly all children of the same age and sex.
Just as significant, most of the children prescribed the drugs were not dealing with weight alone. Researchers reported that 65.2% had at least one illness associated with obesity, including conditions such as high cholesterol, high blood pressure, or sleep apnea. That pattern suggests clinicians are often reserving these medicines for children facing compounded health risks rather than using them broadly in marginal cases.
Why the trend matters
The scale of the increase reflects a larger shift in how obesity is being treated. For years, pediatric obesity care relied heavily on counseling, nutrition support, exercise guidance, and management of related conditions. GLP-1 drugs add a more direct pharmaceutical option to that toolkit. The rapid increase in prescribing indicates that physicians and families are increasingly willing to consider that option, particularly when obesity is severe and already affecting a child’s health.
At the same time, the findings show how early the market still is for this age group. Even after years of rapid growth, use among younger children remains limited. That means the headline is not mass adoption. It is clinical normalization at the margins of a large public health problem. The paper notes that an estimated 20% of children in the U.S. have obesity, defined here as a body mass index above the 95th percentile for children of similar age and sex, without diabetes. Against that backdrop, prescribing to a small fraction of eligible patients can still produce dramatic growth rates.
The study therefore captures an inflection point. Obesity in children is common, but pharmaceutical treatment in preteens is still relatively selective. The increase in GLP-1 use suggests the treatment conversation is changing faster than the total prescribing rate alone might imply.
A first national snapshot for younger children
Researchers describe the work as the first national overview of GLP-1 use among children under 12 in the United States. That gives the study importance beyond the raw numbers. It establishes a baseline for policymakers, insurers, pediatric specialists, and families trying to understand whether these drugs are staying confined to narrow clinical use or moving toward broader adoption.
The current picture points to a middle ground. Prescriptions are rising fast enough to signal meaningful change, but the characteristics of the patients receiving them suggest continued caution in practice. The fact that most treated children had severe obesity and many had obesity-linked illnesses indicates that doctors are not prescribing these medications indiscriminately. Instead, they appear to be concentrated among children with the greatest clinical need.
That matters for the policy debate as well. Public discussion of GLP-1 therapies often swings between two extremes: either they are portrayed as transformational tools that should be used much more widely, or as medicines whose use in children should remain exceptional. The study itself does not resolve that debate. What it does provide is clearer evidence about how treatment is actually unfolding on the ground: slowly in absolute terms, quickly in trend terms, and mainly among more severe cases.
What to watch next
The next questions are likely to center on duration, access, and outcomes. The source material does not provide long-term results for these children, nor does it address how consistently families can obtain the medications over time. But the growth described in the study suggests those questions will become harder to avoid. If prescribing continues to rise, stakeholders will need stronger evidence on which patients benefit most, how early intervention should begin, and how pediatric care systems handle follow-up for children using these drugs.
For now, the most accurate reading is that the U.S. has not entered an era of widespread GLP-1 use among younger children with obesity. It has, however, entered a period in which the use of those drugs is expanding rapidly enough to reshape pediatric obesity treatment decisions. In that sense, the study marks an important transition: not a final verdict on how these medicines should be used in children, but the clearest signal yet that they are moving from the edges of pediatric practice toward a more established role.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
